Update meta-analysis on MMP-7 -181A>G polymorphism and cancer risk: Evidence from 25 studies

Gene

Volumn 521, Issue 2, 2013, Pages 252-258

  Yang, Xueling ^a   Liu, Ya ^a   Yang, Yufeng ^a   Li, Bo ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Cancer risk; Meta analysis; MMP 7; Polymorphism

Indexed keywords

MATRILYSIN;

ARTICLE; CANCER RISK; COLORECTAL CANCER; DNA SEQUENCE; ETHNICITY; GENETIC ASSOCIATION; GENETIC MODEL; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; GYNECOLOGIC CANCER; HETEROZYGOTE; HISTOPATHOLOGY; HOMOZYGOTE; HUMAN; META ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STOMACH CANCER;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MATRIX METALLOPROTEINASE 7; NEOPLASMS; POLYMORPHISM, GENETIC; RISK;

EID: 84876995560     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.03.079     Document Type: Article

References (41)

1. Beeghly-Fadiel A., et al. Common MMP-7 polymorphisms and breast cancer susceptibility: a multistage study of association and functionality. Cancer Res. 2008, 68:6453-6459.
2. Beeghly-Fadiel A., et al. Genetic polymorphisms in the MMP-7 gene and breast cancer survival. Int. J. Cancer 2009, 124:208-214.
3. de Lima J.M., et al. E-cadherin and metalloproteinase-1 and -7 polymorphisms in colorectal cancer. Int. J. Biol. Markers 2009, 24:99-106.
4. Decock J., Paridaens R., Ye S. Genetic polymorphisms of matrix metalloproteinases in lung, breast and colorectal cancer. Clin. Genet. 2008, 73:197-211.
5. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 1986, 7:177-188.
6. Deryugina E.I., Quigley J.P. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006, 25:9-34.
7. dos Reis S.T., et al. Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer. J. Urol. 2009, 181:2320-2325.
8. Dziki L., et al. A/G polymorphism of the MMP-7 gene promoter region in colorectal cancer. Pol. Przegl. Chir. 2011, 83:622-626.
9. Egger M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
10. Fang W.-L., et al. Association of matrix metalloproteinases 1, 7, and 9 gene polymorphisms with genetic susceptibility to colorectal carcinoma in a Han Chinese population. DNA Cell Biol. 2010, 29:657-661.
11. Ghilardi G., et al. Colorectal carcinoma susceptibility and metastases are associated with matrix metalloproteinase-7 promoter polymorphisms. Clin. Chem. 2003, 49:1940-1942.
12. Higgins J.P., et al. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
13. Jaboin J.J., et al. The matrix metalloproteinase-7 polymorphism rs10895304 is associated with increased recurrence risk in patients with clinically localized prostate cancer. Int. J. Radiat. Oncol. 2011, 79:1330-1335.
14. Jormsjo S., et al. Allele-specific regulation of matrix metalloproteinase-7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients. Arterioscler. Thromb. Vasc. Biol. 2001, 21:1834-1839.
15. Kim J.H., et al. Study on association between single nucleotide polymorphisms of MMP7, MMP8, MMP9 genes and development of gastric cancer and lymph node metastasis. Korean J. Gastroenterol. 2011, 58:245.
16. Koskensalo S., et al. MMP-7 overexpression is an independent prognostic marker in gastric cancer. Tumour Biol. 2010, 31:149-155.
17. Kubben F.J.G.M., et al. Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. Br. J. Cancer 2006, 95:744-751.
18. Li Y., et al. Polymorphisms in the promoter regions of the matrix metalloproteinases-1, -3, -7, and -9 and the risk of epithelial ovarian cancer in China. Gynecol. Oncol. 2006, 101:92-96.
19. Li J.Y., Tian M.M., Zhao A.L. Polymorphism in the promoter region of the metalloproteinase-7 increases susceptibility and risk of metastasis of gastric adenocarcinoma. Gastroenterology 2008, 134:A603.
20. Lievre A., et al. Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma. BMC Cancer 2006, 6:270.
21. Lu Z.Q., et al. Correlations of polymorphisms in matrix metalloproteinase-3 and -7 promoters to susceptibility to brain astrocytoma. Ai Zheng 2007, 26:463-468.
22. Malik M.A., et al. Association of matrix metalloproteinase-7 (-181A>G) polymorphism with risk of esophageal squamous cell carcinoma in Kashmir Valley. Saudi J. Gastroenterol. 2011, 17:301-306.
23. Malik M.A., Zargar S.A., Mittal B. Role of the metalloproteinase-7 (181A>G) polymorphism in gastric cancer susceptibility: a case control study in Kashmir valley. Asian Pac. J. Cancer Prev. 2011, 12:73-76.
24. Mantel N., Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959, 22:719-748.
25. Ohtani H. Functional polymorphisms in the promoter regions of matrix metalloproteinase-2,-3,-7,-9 and TNF- alpha genes, and the risk of colorectal neoplasm in Japanese. Yonago Acta Med. 2009, 52:47-56.
26. Peng B., et al. Meta-analysis of association between matrix metalloproteinases 2, 7 and 9 promoter polymorphisms and cancer risk. Mutagenesis 2010, 25:371-379.
27. Qiu W., et al. No association of MMP-7, MMP-8, and MMP-21 polymorphisms with the risk of hepatocellular carcinoma in a Chinese population. Cancer Epidemiol. Biomark. 2008, 17:2514-2518.
28. Sang Q.A., Bodden M.K., Windsor L.J. Activation of human progelatinase A by collagenase and matrilysin: activation of procollagenase by matrilysin. J. Protein Chem. 1996, 15:243-253.
29. Sharma K.L., et al. Higher risk of matrix metalloproteinase (MMP-2, 7, 9) and tissue inhibitor of metalloproteinase (TIMP-2) genetic variants to gallbladder cancer. Liver Int. 2012, 32:1278-1286.
30. Singh H., Jain M., Mittal B. MMP-7 (-181A>G) promoter polymorphisms and risk for cervical cancer. Gynecol. Oncol. 2008, 110:71-75.
31. Sires U.I., et al. Matrilysin is much more efficient than other matrix metalloproteinases in the proteolytic inactivation of alpha 1-antitrypsin. Biochem. Biophys. Res. Commun. 1994, 204:613-620.
32. Srivastava P., et al. Bladder cancer risk associated with genotypic polymorphism of the matrix metalloproteinase-1 and 7 in North Indian population. Dis. Markers 2010, 29:37-46.
33. Sugimoto M., et al. Polymorphisms of matrix metalloproteinase-7 and chymase are associated with susceptibility to and progression of gastric cancer in Japan. J. Gastroenterol. 2008, 43:751-761.
34. Vairaktaris E., et al. High gene expression of matrix metalloproteinase-7 is associated with early stages of oral cancer. Anticancer Res. 2007, 27:2493-2498.
35. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ. Res. 2003, 92:827-839.
36. Wang W.S., et al. Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma. Carcinogenesis 2006, 27:1113-1120.
37. Woo M., et al. Clinical implications of matrix metalloproteinase-1, -3, -7, -9, -12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer. J. Gastroenterol. Hepatol. 2007, 22:1064-1070.
38. Wu S., et al. Correlation of polymorphism of IL-8 and MMP-7 with occurrence and lymph node metastasis of early stage cervical cancer. J. Huazhong Univ. Sci. Technol. Med. Sci. 2011, 31:114-119.
39. Yi Y.C., et al. Matrix metalloproteinase-7 (MMP-7) polymorphism is a risk factor for endometrial cancer susceptibility. Clin. Chem. Lab. Med. 2010, 48:337-344.
40. Yuan-Yuan M., Li-Feng Z., Li-Jie Z. MMP7 -181G allele is a low-penetrant risk factor for cancer development in East Asians. DNA Cell Biol. 2012, 31:772-776.
41. Zhang J. The functional polymorphism in the matrix metalloproteinase-7 promoter increases susceptibility to esophageal squamous cell carcinoma, gastric cardiac adenocarcinoma and non-small cell lung carcinoma. Carcinogenesis 2005, 26:1748-1753.